| Source of record | UK Trials |
| ISRCTN | ISRCTN46778796 |
| Date ISRCTN assigned | 19/08/2002 |
| Local reference number(s) | LY2 |
| Public title | Randomised Comparison of Cyclical Anthracycline-Based Chemotherapy [PA(BI)OE] with Alternating Chemotherapy [ChlVPP/PABIOE] in Advanced Hodgkin's Disease |
| Scientific title |
|
| Acronym | Not Applicable |
| Disease/condition/study domain | Lymphoma (Hodgkin's) |
| Study hypothesis | Not provided at time of registration |
| Design/methodology | Randomised controlled trial |
| Research ethics review | Not provided at time of registration |
| Countries of trial | United Kingdom |
| Participants - inclusion criteria | 1. All previously untreated and properly staged patients aged between 15 and 69 years (inclusive) with Hodgkin's disease for whom chemotherapy is indicated are eligible for this trial, ie Stage I & IIA (poor prognosis), IB, IIB, III, IV
2. Patients must be free from any irreversible medical condition that would drastically limit their life span or prohibit the use of combination chemotherapy. This applies particularly to elderly patients
3. Adequate long term follow-up must be possible |
| Participants - exclusion criteria | Not provided at time of registration |
| Patient information material |
|
| Anticipated end date | 30/04/1996 |
| Status of trial | Completed |
| Target number of participants | Not provided at time of registration |
| Interventions | 1. PA(BI)OE Regimen: Multi-drug chemotherapy with adriamycin, vincristine, prednisolone, etoposide and bleomycin [PA(BI)OE] cycle repeated every 21 days. A minimum of six courses to be given with at least two following documentation of clinical complete remission and a maximum of eight courses. Bleomycin to be given for the first four courses only.
2. ChlVPP/PABIOE Regimen: Multi-drug chemotherapy with chlorambucil, procarbazine, prednisolone and vinblastine (ChIVPP) alternating every 21 days with PABIOE. |
| Primary outcome measure(s) | Not provided at time of registration |
| Secondary outcome measure(s) | Not provided at time of registration |
| Sources of funding | British National Lymphoma Investigation, Central Lymphoma Group |
| Sponsor name | British National Lymphoma Investigation (BNLI) |
| Sponsor details | CRC and UCL Cancer Trials Centre
222 Euston Road
London
United Kingdom
NW1 2DA |
| Sponsor telephone | +44(0)20 7679 8060 |
| Sponsor fax | +44(0)20 7679 8061 |
| Sponsor email | bnli@ctc.ucl.ac.uk |
| Sponsor website | http://www.bnli.ucl.ac.uk |
| Contact name | Dr - - |
| Contact details | UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA |
| Contact telephone | +44 (0) 20 7670 4723 |
| Contact fax | +44 (0) 20 7670 4818 |
| Contact email | register@ctu.mrc.ac.uk |
| More information | For more up-to-date information please go to the ISRCTN link below. |
| Link to record in ISRCTN Register | ISRCTN46778796 |
| Date last extracted from ISRCTN register | 17/04/2008 |
